MedTrace Logo

Transcranial Ultrasound in Clinical SONothrombolysis

NCT00504842 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2008-04-15

No results posted yet for this study

Summary

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

MRX-801

DRUG

Placebo

Sponsors & Collaborators

  • ImaRx Therapeutics

    lead INDUSTRY

Principal Investigators

  • Carlos Molina Cateriano, MD · University Hospital Vall d'Hebron, Barcelona, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Completion
2008-03-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504842 on ClinicalTrials.gov